However, none of them has displayed a convincing advancement in AML treatment as a single drug.10 Responses were mostly limited to transient reductions in peripheral blood blasts, and bone marrow responses were very rare.11, 12 Limited response to the FLT3 inhibitors could be due to several reasons. This evidence concerns the gene FLT3 and acute myeloid leukemia.